Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 451 - 500 av 504 resultater
Tid
Selskap
Tittel
Sektor
Kategori
08 Sep 2021
07:00 CEST
SANOFI
Sanofi va acquérir Kadmon pour renforcer la croissance de son activité Transplantation
20103015 Pharmaceuticals
Other subject
08 Sep 2021
07:00 CEST
SANOFI
Sanofi to acquire Kadmon to further strengthen growth of transplant business
20103015 Pharmaceuticals
Other subject
30 Aug 2021
07:00 CEST
SANOFI
Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
20103015 Pharmaceuticals
Other subject
30 Aug 2021
07:00 CEST
SANOFI
Un essai pivot consacré à Dupixent (dupilumab) atteint tous ses critères d’évaluation primaires et secondaires ; Dupixent devient le premier médicament biologique permettant une réduction significative des signes et symptômes de la dermatit
20103015 Pharmaceuticals
Other subject
25 Aug 2021
18:31 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares - July 2021
20103015 Pharmaceuticals
Share history
25 Aug 2021
18:31 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2021
20103015 Pharmaceuticals
Share history
06 Aug 2021
17:42 CEST
SANOFI
FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
20103015 Pharmaceuticals
Other subject
06 Aug 2021
17:42 CEST
SANOFI
La FDA approuve Nexviazyme® (avalglucosidase alpha-ngpt), nouvelle option thérapeutique importante pour la forme tardive de la maladie de Pompe
20103015 Pharmaceuticals
Other subject
05 Aug 2021
12:00 CEST
SANOFI
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
20103015 Pharmaceuticals
Other subject
05 Aug 2021
12:00 CEST
SANOFI
Arrêt prématuré de l’essai de phase III de Libtayo® (cemiplimab) en association avec une chimiothérapie dans le traitement du cancer du poumon non à petites cellules au stade avancé en raison d’une forte amélioration de la survie globale
20103015 Pharmaceuticals
Other subject
03 Aug 2021
07:00 CEST
SANOFI
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
20103015 Pharmaceuticals
Other subject
03 Aug 2021
07:00 CEST
SANOFI
Sanofi va acquérir Translate Bio et accélère le déploiement de la technologie de l’ARNm dans le développement de vaccins et d’agents thérapeutiques
20103015 Pharmaceuticals
Other subject
29 Jul 2021
18:24 CEST
SANOFI
Mise en ligne du rapport financier semestriel 2021 de Sanofi
20103015 Pharmaceuticals
Other subject
29 Jul 2021
18:24 CEST
SANOFI
Online availability of Sanofi’s half-year financial report for 2021
20103015 Pharmaceuticals
Other subject
29 Jul 2021
07:31 CEST
SANOFI
Sanofi nomme deux nouveaux dirigeants au Comité Exécutif et annonce la future Présidente d'EUROAPI
20103015 Pharmaceuticals
Other subject
29 Jul 2021
07:31 CEST
SANOFI
Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI
20103015 Pharmaceuticals
Other subject
29 Jul 2021
07:30 CEST
SANOFI
Accélération des ventes - Perspectives 2021 revues à la hausse
20103015 Pharmaceuticals
Other subject
29 Jul 2021
07:30 CEST
SANOFI
Sales growth accelerated - Full-year guidance raised
20103015 Pharmaceuticals
Other subject
29 Jul 2021
07:00 CEST
SANOFI
Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients
20103015 Pharmaceuticals
Other subject
29 Jul 2021
07:00 CEST
SANOFI
Dupixent®(dupilumab) améliore significativement les démangeaisons et l’urticaire des patients souffrant d’urticaire chronique spontanée–un pas de plus vers la démonstration du rôle de l’inflammation de type 2 dans cette catégorie de patient
20103015 Pharmaceuticals
Other subject
22 Jul 2021
18:02 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares - June 2021
20103015 Pharmaceuticals
Share history
22 Jul 2021
18:02 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juin 2021
20103015 Pharmaceuticals
Share history
13 Jul 2021
07:30 CEST
SANOFI
Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris
20103015 Pharmaceuticals
Other subject
13 Jul 2021
07:30 CEST
SANOFI
Sanofi devient partenaire Premium des Jeux Olympiques et Paralympiques de Paris 2024
20103015 Pharmaceuticals
Other subject
30 Jun 2021
18:00 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares - May 2021
20103015 Pharmaceuticals
Share history
30 Jun 2021
18:00 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2021
20103015 Pharmaceuticals
Share history
29 Jun 2021
10:00 CEST
SANOFI
Sanofi launches dedicated vaccines mRNA Center of Excellence
20103015 Pharmaceuticals
Other subject
29 Jun 2021
10:00 CEST
SANOFI
Sanofi annonce la création d’un Centre d’excellence dédié aux vaccins à ARNm
20103015 Pharmaceuticals
Other subject
28 Jun 2021
08:00 CEST
SANOFI
Premiers résultats positifs pour le nirsevimab contre le VRS dans le cadre de l’essai MEDLEY de phase II/III
20103015 Pharmaceuticals
Other subject
28 Jun 2021
08:00 CEST
SANOFI
Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
20103015 Pharmaceuticals
Other subject
28 Jun 2021
07:00 CEST
SANOFI
Mise à jour du RPC de Dupixent® (dupilumab) avec des données de long terme qui confortent son profil de sécurité bien établi chez l’adulte atteint de dermatite atopique modérée à sévère
20103015 Pharmaceuticals
Other subject
28 Jun 2021
07:00 CEST
SANOFI
Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
20103015 Pharmaceuticals
Other subject
25 Jun 2021
07:30 CEST
SANOFI
Sanofi : Mise en ligne du document «Q2 2021 Memorandum for modelling purposes»
20103015 Pharmaceuticals
Other subject
25 Jun 2021
07:30 CEST
SANOFI
Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
20103015 Pharmaceuticals
Other subject
25 Jun 2021
07:15 CEST
SANOFI
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
20103015 Pharmaceuticals
Other subject
25 Jun 2021
07:15 CEST
SANOFI
Sanofi : La Commission européenne approuve Libtayo® (cemiplimab), premier médicament d’immunothérapie indiqué pour le traitement du carcinome basocellulaire au stade avancé
20103015 Pharmaceuticals
Other subject
25 Jun 2021
07:00 CEST
SANOFI
Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
20103015 Pharmaceuticals
Other subject
25 Jun 2021
07:00 CEST
SANOFI
Sanofi : La Commission européenne approuve Libtayo® (cemiplimab) pour le traitement de première ligne du cancer du poumon non à petites cellules exprimant ≥50 % de cellules tumorales PD-L1 positives
20103015 Pharmaceuticals
Other subject
18 Jun 2021
15:45 CEST
SANOFI
European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
20103015 Pharmaceuticals
Other subject
18 Jun 2021
15:45 CEST
SANOFI
La Commission européenne approuve Aubagio® (tériflunomide), premier médicament par voie orale pour le traitement de première ligne de la sclérose en plaques récurrente-rémittente de l’enfant et de l’adolescent
20103015 Pharmaceuticals
Other subject
11 Jun 2021
09:00 CEST
SANOFI
Les nouvelles données pivots présentées au Congrès de l’EHA 2021 confirment que le sutimlimab, premier inhibiteur expérimental de la fraction C1s
20103015 Pharmaceuticals
Other subject
11 Jun 2021
09:00 CEST
SANOFI
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia
20103015 Pharmaceuticals
Other subject
07 Jun 2021
18:00 CEST
SANOFI
Sanofi launches its new global employee share ownership plan
20103015 Pharmaceuticals
Other subject
07 Jun 2021
18:00 CEST
SANOFI
Sanofi lance son nouveau plan mondial d’actionnariat salarié
20103015 Pharmaceuticals
Other subject
04 Jun 2021
07:00 CEST
SANOFI
Sanofi s’associe à de grands groupes coopératifs universitaires pour étudier l’amcénestrant dans le traitement adjuvant du cancer du sein positif pour les récepteurs des œstrogènes
20103015 Pharmaceuticals
Other subject
04 Jun 2021
07:00 CEST
SANOFI
Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
20103015 Pharmaceuticals
Other subject
03 Jun 2021
14:00 CEST
SANOFI
Sanofi lance un fonds Planet Mobilization de 3 millions d'euros pour soutenir les projets environnementaux de ses collaborateurs
20103015 Pharmaceuticals
Other subject
03 Jun 2021
14:00 CEST
SANOFI
Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects
20103015 Pharmaceuticals
Other subject
01 Jun 2021
07:00 CEST
SANOFI
Sanofi fait le point sur le programme clinique consacré au venglustat
20103015 Pharmaceuticals
Other subject
01 Jun 2021
07:00 CEST
SANOFI
Sanofi provides update on venglustat clinical program
20103015 Pharmaceuticals
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
9
10
11
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva